Indium- 111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)- dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma

Journal of Nuclear Medicine

Volumn 39, Issue 11, 1998, Pages 1907-1909

  Kurtaran, Amir ^a   Scheuba, Christian ^b   Kaserer, Klaus ^b   Schima, Wolfgang ^b   Czerny, Christian ^b   Angelberger, Peter ^b   Niederle, Bruno ^b   Virgolini, Irene ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Indium 111 diethylenetdamine pentaacetic acid D Phe 1 octreotide; Lymph node metastases; Medullary thyroid carcinoma; Technetium 99m(V)dimercaptosuccinic acid

Indexed keywords

PENTETREOTIDE IN 111; SUCCIMER TC 99M;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION;

CARCINOMA, MEDULLARY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OCTREOTIDE; PENTETIC ACID; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; THYROID NEOPLASMS;

EID: 0031797968     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. Medicine 1984;63:319-342.
2. Jensen MH, Davis RK, Derrick L. Thyroid cancer: a computer-assisted review of 5287 cases. Otolaryngol Head Neck Surg 1990;102:51-53.
3. Vierhapper H, Raber W, Bieglmayer, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997;82:1589-1593.
4. 123I-vasoactive intestinal peptide in the localization diagnosis of medullary thyroid carcinoma. Nucl Med Biol 1996;23:503-507.
5. Wells SA, Dilley WG, Farndon JA, et al. Early diagnosis and treatment of medullary carcinoma. Arch Intern Med 1985;145:1248-1252.
6. van Heerden JA, Grand CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212:395-401.
7. Moley JF, Wells SA, Dilley WG, et al. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993;114:1090-1096.
8. Raue F, Winter J, Frank-Raue K, et al. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res 1989;21(suppl):31-34.
9. Tisell LE, Hansson G, Jansson S. Surgical treatment of medullary carcinoma of the thyroid. Horm Metab Res 1989;21(suppl):29-31.
10. Chong GC, Beahrs OH, Sizemore GW, et al. Medullary thyroid carcinoma of the thyroid gland. Cancer 1975;35:695-704.
11. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63.
12. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-121.
13. Schröder S, Dralle H. Prognostic factors in medullary thyroid carcinomas. Horm Metab Res 1989;21(suppl):26-28.
14. Hoefnagel CA, Delprat CC, Zanin, et al. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 1988;13:159-165.
15. 99mTc-MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988;29:33-38.
16. Lebouthiller G, Morais J, Picard M, et al. Tc-99m-sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med 1993;18: 657-661.
17. 111 In-labeled anti-CEA monoclonal antibody fragments. Nucl Med Commun 1992;13:142-148.
18. 99mTc(V)-dimercapto-succinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995;144:339-345.
19. Ohta H, Yamamota K, Endo K, et al. A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 1984;25:323-325.
20. Parthasarathy KL, Shirmaoka K, Bakshi SP, et al. Radiotracer uptake in medullary carcinoma of the thyroid. Clin Nucl Med 1980;5:45-48.
21. Senga O, Miyakawa M, Shirota H, et al. Comparison of Tl-201-chloride and Ga-67-citrate scintigraphy in the diagnosis of thyroid tumor: concise communication. J Nucl Med 1982;23:225-228.
22. Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single photon emission tomography dimercaptosuccinic acid. Surgery 1993;114:1083-1089.
23. Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling catheterisation for localization of persisting medullary thyroid carcinoma. Br J Cancer 1994;69:1141-1144.
24. Anderson RJ, Sizcmore GW, Wahner HW, et al. Thyroid scintigraphy in familial medullary carcinoma of the thyroid gland. Clin Nucl Med 1978;3:147-151.
25. 131I-MIBG and medullary carcinoma of the thyroid. Lancet 1984;2:273-274.
26. 2 fragments of anticarcino-embryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992;74:157-163.
27. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-1121.
28. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989;1:242-244.
29. Dorr U, Frank-Raue K, Sautter-Bihl ML, Guzman G, Buhr HJ, Bihl H. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993;14:439-445.
30. 111In-octreotide scintigraphy in oncology. Digestion 1993;54:84-87.
31. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-1417.
32. Reubi JC, Chayvialle JA, Franc B, et al. Somatostutin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:567-573.
33. Frank-Raue K, Raue F, Buhr HJ, et al. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 1992;2:113-117.
34. Rohrer L, Raulf F, Bruns C, et al. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993;90:4196-4200.
35. 111In-DTPA-D-Phe-1-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-1591.
36. Behr TM, Gratz S, Markus PM, et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (chimney sign) in occult metastatic medullary thyroid cancer: a typical site of tumor manifestation? Eur J Nucl Med 1997;24:184-191.
37. Tisell L, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-66.
38. Buhr HJ, Lehnert T, Raue F. New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. Eur J Surg Oncol 1990;16:366-369.
39. Jackson CE, Talpos GB, Kambouris JB, et al. The clinical course after definitive operation for medullary thyroid carcinoma. Surgery 1983;94:995-1001.
40. Baylin SB, Wells SA. Management of hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 1981;10:367-378.
41. Ellenhorn JDI, Shah JP, Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993;114:1078-1082.
42. Gimm O, Dralle H. Medullary thyroid cancer: reoperation. Acta Chir Austriaca 1997;29:15-17.
43. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR 1991;158:961-969.